Published by
The Street
The Street
By Dan Weil Wood’s Ark Investment Management bought a series of biotech stocks, as it has done repeatedly in recent sessions. Renowned investor Cathie Wood, chief executive officer of Ark Investment Management, again bought biotechnology stocks Wednesday, including one that programs cells with DNA as code. Ark also repeated its buy of a spectrometry fund. All valuations below are as of Wednesday’s close. The biotech company programing cells is Ginkgo Bioworks (DNA) . Ark funds purchased 1.55 million shares of the company, valued at $5.9 million. Ginkgo’s Explanation On its web site, Ginkgo say…
